Clinical Trial in Need of Patients -- Firm Studying Drug for Aggressive Breast Cancer
The Commercial Appeal (2007-Current) › December 28, 2009
Linked as:
Summary
Researchers have begun enrolling Memphis-area patients in a clinical trial on a drug that appears to offer the best hope yet for treating a particularly aggressive form of breast cancer that's most common among African-American women.
The Nashville-based Sarah Cannon Research Institute is conducting the trial of the use of ixabepilone, a drug with the trade name Ixempra, to treat "triple-negative" breast cancer.See the full content of this document
Extract
Clinical Trial in Need of Patients -- Firm Studying Drug for Aggressive Breast Cancer
The disease - so named because tumor cells lack the tell-tale signs of three proteins common to other types of breast ...
See the full content of this document
Sponsored links
